Benefits

Prostate Px is useful to physicians because it provides objective analysis of the patient’s biopsy tissue enabling more-informed, actionable decisions prior to prostate cancer treatment selection.

Primary Benefits

• A subset of patients who present clinically as low-risk (biopsy Gleason <6, PSA <10 ng/ml, clinical stage T1, T2a) can have aggressive disease: Prostate Px can unmask these high-risk cases
• Patients classified by American Urological Association (AUA) guidelines as medium or intermediate-risk can now be assessed as high or low-risk prior to prostate cancer treatment selection
• Prostate Px can assess favorable pathology
• Prostate Px provides an objective recurrence score that can be used to support patient counseling

Additional Benefits

Prostate Px provides useful information for all surgical candidates even though patients may select a non-surgical alternative.

• Unlike prostatectomy, patients considering radiotherapy (EBRT or brachytherapy) will only have one biopsy-based tissue view of the disease: radiotherapy treatments destroy the tissue. Prostate Px provides a unique perspective on these patients' disease severity, prior to therapy, that is unavailable by any other method
• Patients considering brachytherapy, active surveillance or cryotherapy, as well as surgery can make more informed decisions based upon Prostate Px results